Insights into the Use of CDK 4/6 Inhibitors in Patients with HR-positive Advanced or Metastatic Breast Cancer

Katarzyna Anna Rygiel

Abstract


Hormone receptor (HR)-positive breast cancer (BC) is the most common subtype of BC and some patients with such tumors experience recurrences. Endocrine-based therapy (ET) (e.g., tamoxifen, aromatase inhibitors (AIs), and fulvestrant) that has improved outcomes in such patients represents the initial therapy for women with HR-positive/human epidermal growth factor receptor 2 (HER2)-negative BC (considering no evidence of visceral crisis). However, the resistance to ET can occur in almost 50% of HR-positive BCs. In order to improve outcomes of patients with HR-positive metastatic BC, new treatment strategies are required. One such therapy is the new class of medications, cyclin-dependent kinase (CDK) 4/6 inhibitors, that have improved the outcomes in such patients (both endocrine-sensitive and endocrine-resistant).

This article presents evidence from the main clinical trials, which led to the approval of palbociclib, ribociclib, and abemaciclib. These three CDK 4/6 inhibitors have shown a significant improvement of the progression-free survival (PFS) in patients with HR-positive/HER2-negative metastatic BC when used in combination with selected ETs. In addition, some important patient management considerations, when choosing a particular CDK 4/6 inhibitor for an individual patient are presented. Furthermore, a need to find biomarkers for CDK 4/6 inhibitor sensitivity, efficacy, and resistance, to be able to precisely select the best patient-candidates for this treatment is highlighted.


Keywords


Hormone receptor (HR)-positive breast cancer (BC); metastatic BC; cyclin-dependent kinase (CDK) 4/6 inhibitors; palbociclib; ribociclib; abemaciclib; biomarkers

Full Text:

PDF

References


Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.

Pan H, Gray R, Braybrooke J, et al.; EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836-1846.

Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer:American Society of Clinical Oncology guideline. J Clin Oncol 2016;34:3069-103.

Brufsky AM, Dickler MN. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist 2018;23:1-12.

Shah M, Nunes MR, Stearns V. CDK 4/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park)2018;32:216-22.

VanArsdale T, Boshoff C, Arndt KT. et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res 2015;21(13):2905-10.

Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.

Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-219.

Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-36.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541-1547.

Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018.pii:S1470-2045(18)30292-4.

Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018 Jun 3:JCO2018789909.

Sledge GWJr, Toi M, Neven P et al. MONARCH 2:abemaciclib in combination with fulvestrant in women with HR1/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875-2884.

Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2-negative metastatic breast cancer. Clin Cancer Res 2017;23:5218-5224.

Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638-3646.

Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the blackwhite crossover. J Natl Cancer Inst 2012;104:1094-1101.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 2, 2018.

Zhang X H-F, Giuliano M, Trivedi MV, et al. Metastasis dormancy in estrogen receptor-positive breast cancer. ClinCancer Res 2013;19:6389-6397.

Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 2018;25(4):392-401.

Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006;9:23-32.

Matikas A, Foukakis T, Bergh J. Tackling endocrine resistance in ER-positive HER2-negative advanced breastcancer: a tale of imprecision medicine. Crit Rev Oncol Hematol 2017;114:91-101.

Finn RS, Aleshin A, Slamon, DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 2016;18:17.

Goldschmidt D, Dalal AA, Romdhani H, et al. Current treatment patterns among postmenopausal women with HR+/HER2- metastatic breast cancer in US community oncology practices: an observational study. Adv Ther 2018;35:482-493.

Han HS, Magliocco AM. Molecular testing and the pathologist's role in clinical trials of breast cancer. Clin Breast Cancer 2016;16:166-179.

Abbosh C, Swanton C, Birkbak NJ. Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Ann Oncol 2018;29:535-537.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).Breast Cancer. V3.2017. https://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Published November 10,2017. Accessed December 1, 2018.

Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat 2014;147:617-629.

Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast 2016;26:87-99.

Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer:risk factors, presentation, characteristics and management.J Res Pharm Pract 2014;3:12-18.

Rugo HS, Turner NC, Finn RS. Pooled analysis of randomised PALOMA clinical studies. Eur J Cancer 2018;101:123-133.

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016;13:417-30.

ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer (PARSIFAL). Available from:https://clinicaltrials.gov/ct2/show/NCT02491983. Accessed December 2, 2018.




DOI: http://dx.doi.org/10.30564/amor.v4i4.193

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Katarzyna Anna Rygiel

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.